| Excerpt | Reference |
|---|
| "Testicular tumors are generally characterized by a loss of responsiveness to gonadotropins." | ( Ascoli, M; Puett, D, 1978) |
| "Primary testicular neoplasms are not common childhood tumors, comprising about 1% of all childhood malignancies [1]." | ( Chu, JY; DeMello, D; McElfresh, AE; O'Connor, DM; Razek, AA, 1978) |
| "Testicular cancer is divided pathologically into two categories; seminoma and non-seminomatous germ cell tumor (NSGCT)." | ( Ishikawa, H; Ishikawa, S; Kanoh, S; Koiso, K; Nemoto, R; Ohtani, M, 1986) |
| "Advanced testicular cancer is best treated with combination platinum based chemotherapy as primary therapy." | ( Donohue, JP; Rowland, RG, 1985) |
| "Advanced testicular cancer is best treated with cisplatinum-based combination chemotherapy." | ( Kotake, T; Miki, T, 1987) |
| "More than 90% of testicular neoplasms are of germ-cell origin; about 40% of cases involve pure seminoma, 15%-20% are pure embryonal carcinoma, and the rest are of mixed types." | ( Bergmann, KA, 1987) |
| "Disseminated testis cancer is a landmark adult solid tumor because of its high curability." | ( Einhorn, LH; Loehrer, PJ; Nichols, CR; Roth, BJ; Williams, SD, 1989) |
| "Testicular cancer is associated with undescended testis and possibly other urogenital anomalies." | ( Morrison, AS, 1987) |
| "Testicular tumor is a rare diseases in Japan." | ( Kotake, T; Miki, T, 1984) |
| "Bilateral testicular tumors are known to occur in congenital adrenal hyperplasia, but their steroidogenic properties are not well studied." | ( Antonipillai, I; Franco-Saenz, R; Kropp, K; McCorquodale, M; Mulrow, PJ; Tan, SY, 1981) |
| "Testicular cancers are associated frequently with endocrinologic manifestations, which may be more disabling to the patient than the malignant potential of the tumor, especially with childhood Leydig cell tumors." | ( Pearson, JC, 1981) |
| "Treatment for testicular cancer is associated with a small, but clearly identifiable, risk for secondary solid tumors that can be attributed to radiotherapy, and for secondary leukemia mainly associated with the use of chemotherapy." | ( Bokemeyer, C; Schmoll, HJ, 1995) |
| "Secondary testicular tumors are very rare." | ( Agnanti, N; Bai, M; Giannakopoulos, X; Grammeniatis, E; Stefanou, D, 1994) |
| "Metastatic testicular cancers are curable, whereas bladder cancers and most other solid tumors are not." | ( Chresta, CM; Hickman, JA; Masters, JR, 1996) |
| "Bilateral primary testicular tumors are rare and usually consist of either interstitial cells or hypertrophic testicular adrenal remnant tissue." | ( Kempter, F; Sabanegh, E; Schneider, C; Shekarriz, M; Waldherr, R, 1996) |
| "Nonmetastatic testicular tumors are regularly formed in older GDNF-overexpressing mice." | ( de Rooij, DG; Hess, MW; Hyvönen, ME; Lakso, M; Lindahl, M; Meng, X; Parvinen, M; Pichel, JG; Raatikainen-Ahokas, A; Rauvala, H; Saarma, M; Sainio, K; Sariola, H; Westphal, H, 2000) |
| "Testicular cancer is a rare tumour with the potential for cure at diagnosis." | ( Hain, SF; Huddart, RA; Leslie, MD; O'Doherty, MJ; Partridge, SE; Timothy, AR, 2000) |
| "Although testicular tumors are also induced by some EDCs, such as DES and E2, most of tumors are interstitial cell tumors, but not germ cell tumors, which are most common testicular tumors in man." | ( Imaida, K; Shirai, T, 2000) |
| "Testicular tumors are very rare in boys, approximately 1." | ( Borbás, E; Minik, K; Réti, G; Ságodi, L; Sólyom, E, 2001) |
| "Testicular cancer is the most common neoplasia occurring in the young male population." | ( Bourrouillou, G; Bujan, L; Calvas, P; Daudin, M; De Mas, P; Mieusset, R; Vincent, MC, 2001) |
| "Testis cancer is the most common tumor detected in men aged from 20 to 35 years accounting for 1-2%." | ( Antoniolli, SZ; Bassetto, MA; Curti, P; Maffei, N; Porcaro, AB; Schiavone, D, 2002) |
| "Testicular cancer is remarkable because it is curable by combination cytotoxic chemotherapy even when widely disseminated." | ( Birtle, AJ; Huddart, RA, 2005) |
| "Testicular cancer is a rare disease, accounting for 1." | ( Garner, MJ; Ghadirian, P; Krewski, D; Turner, MC, 2005) |
| "Testicular cancer is the most common solid tumor in young men." | ( Aminsharifi, AR; Kumar, V; Mohamadhoseini, E; Sabayan, B; Samani, S; Talaei, T, 2007) |
| "Incidence of testicular cancer is low in Japan." | ( Akaza, H; Hasegawa, Y; Hattori, K; Hinotsu, S; Kawai, K; Kojima, H; Miyanaga, N; Oikawa, T; Sekido, N; Shimazui, T, 2006) |
| "Human testicular cancer is very sensitive to chemotherapy and radiation therapy and is regarded as a curable cancer." | ( Abarzua, F; Huh, NH; Kumon, H; Nasu, Y; Sakaguchi, M; Takaishi, M; Tanimoto, R, 2007) |
| "The incidence of testicular cancer is increasing throughout the world." | ( Cussenot, O; Gattegno, B; Lakmichi, MA; Niang, L; Sebe, P; Thibault, P; Tligui, M; Traxer, O, 2007) |
| "Testicular tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell rescue, even when this regimen is used as third-line or later therapy or in patients with platinum-refractory disease." | ( Abonour, R; Brames, MJ; Chamness, A; Einhorn, LH; Perkins, SM; Williams, SD, 2007) |
| "Testicular cancer is the most common solid tumor among young men aged 15 to 35 years." | ( Basaran, M; Goren, T; Kurt, R; Oflaz, H; Ozben, B; Sezer, M; Umman, S, 2007) |
| "Testicular cancer is the most common type of cancer among Norwegian 15 to 40-year-old men." | ( Fosså, SD; Lehne, G; Oldenburg, J, 2008) |
| "Testicular cancer is the most common malignancy affecting young men in their third or fourth decade with an incidence of three to six new cases per 100,000 males each year." | ( Casey, RG; Cullen, IM; Hassan, HC; Rogers, E, 2008) |
| "Most patients with testis cancer are cured with treatment." | ( Bestwick, J; Murugaesu, N; Oliver, RT; Powles, T; Shamash, J, 2009) |
| "Testicular cancer is the most common cancer in men age 20-35 years and accounts for approximately 1% of all male malignancies." | ( Carver, BS; Sheinfeld, J, 2009) |
| "About half of testicular cancers are seminomas, which tend to affect older men and have a good prognosis." | ( Neal, RD; Stuart, N; Wilkinson, C, 2007) |
| "Necrotic testicular tumors are relatively frequent and can present a significant diagnostic challenge." | ( Epstein, JI; Lee, TK; Miller, JS; Ulbright, TM, 2009) |
| "Paratesticular tumors are rare and polymorphous." | ( Hunald, F; Malinirina Ralahy, F; Rakoto-Ratsimba, HN; Rakototiana, A; Rakotovao, M; Rantomalala, HY; Samison, LH, 2009) |
| "Although testicular cancers are highly curable malignancies, conventional cisplatin based therapy often causes important toxicities, not often easily manageable." | ( Bauer, C; Bousquet, G; Le Maignan, C; Lejri, N; Lokiec, F; Misset, JL; Pouliquen, AL, 2011) |
| "Testicular tumors are a rare condition associated with congenital adrenal hyperplasia (CAH), originated from intratesticular adrenal rest tumors, and they are rarely associated with malignant tumors." | ( Barros, AI; Fernandes, VO; Ferreira, FV; Fontenele, EG; Montenegro, AP; Montenegro, RM; Quidute, AR; Sales, AP, 2009) |
| "Testicular cancer is a rare tumor, subdivided into seminomatous and nonseminomatous tumors." | ( Becherer, A, 2011) |
| "Testicular cancer is the most common solid tumor among men aged 15-35 years." | ( Fung, C; Vaughn, DJ, 2011) |
| "Most testicular cancers are germ cell tumours and half of these are seminomas, which tend to affect older men and have a good prognosis." | ( Chung, P; Warde, P, 2011) |
| "Testicular cancer is highly curable with cisplatin-based therapy, and testicular cancer-derived human embryonal carcinoma (EC) cells undergo a p53-dominant transcriptional response to cisplatin." | ( Beyrouthy, MJ; Desai, D; Freemantle, SJ; Haghkerdar, JM; Hever, MP; Kerley-Hamilton, JS; Mao, P; Niemaszyk, LM; Spinella, MJ; Yanco, EG, 2011) |
| "Germ cell testicular cancer is understood to arise during embryogenesis, based on the persistence of embryonic germ cell markers in carcinoma in situ and seminoma." | ( Itman, C; Jaiprakash, A; Kitazawa, R; Looijenga, LH; Loveland, KL; Mithraprabhu, S; Young, JC, 2011) |
| "Testicular cancer is the most frequent cancer in patients between 20 and 40 years of age." | ( Doehn, C; Jocham, D; Keller, T; Neumann, A, 2011) |
| "Testicular cancer is the most common cancer in men under 35 years of age, and has the highest survival for adult male malignancies." | ( Coleman, MP; Cooper, N; Mason, M; Nur, U; Oliver, T; Parmar, MK; Rachet, B; Read, G; Stenning, S; Sydes, MR, 2012) |
| "Testicular cancer is the most common form of cancer among men of reproductive age and has a high cure rate associated with chemotherapy treatment with bleomycin, etoposide, and cis-platinum (BEP)." | ( Chan, D; Delbès, G; Landry, M; Robaire, B; Trasler, JM, 2012) |
| "Testicular cancer is the most common cancer among young men of reproductive age." | ( Cort, A; Kucuksayan, E; Ozben, T; Ozdemir, E; Timur, M, 2012) |
| "Testicular cancer is a very common cancer in males aged 15-44 years." | ( Cort, A; Ozben, T; Ozdemir, E; Timur, M, 2012) |
| "Testicular cancer is the most common cancer among young men of reproductive age." | ( Cort, A; Ozben, T; Ozdemir, E; Timur, M, 2013) |
| "Testicular cancer is one of the commonest cancers in men of working age, and is increasing in incidence in Europe and North America." | ( Behrens, T; Dreger, S; Fritschi, L; Hense, S; Mester, B, 2010) |
| "Testicular cancer is the most frequent cancer in young men aged 15-40 years and accounts for 1% of all cancer diagnosed in males." | ( Bowles, J; Koopman, P; Spiller, CM, 2013) |
| "Testicular cancer is the most frequent solid malignant tumour type in men 20-40 years of age." | ( de Jong, S; Gietema, JA; Koster, R; Timmer-Bosscha, H; van Vugt, MA, 2013) |
| "Testicular cancer is the most common malignancy in young men (15-29 years old)." | ( Aytekin, V; Karabay, KO; Yildiz, O, 2014) |
| "Benign testicular tumors are frequent incidental findings." | ( Barbagallo, F; Cantisani, V; Franco, G; Gianfrilli, D; Giannetta, E; Isidori, AM; Lemma, A; Lenzi, A; Lombardo, F; Manganaro, L; Martino, G; Pofi, R; Pozza, C, 2014) |
| "Testicular cancer is the most common cancer in young males." | ( Géczi, L; Küronya, Z; Németh, H, 2014) |
| "Testicular tumors are very common among man under the age of 45 years." | ( Gupta, N; Yadav, S, 2014) |
| "Testicular tumors are representative solid cancers that occur in young men, and the standard multi-drug combination chemotherapy has been established for metastatic tumors." | ( Ichioka, D; Ikeda, A; Joraku, A; Kawai, K; Kojima, T; Kojyo, K; Kurobe, M; Miyazaki, J; Nishiyama, H; Shiga, M; Suetomi, T; Tsutsumi, M; Yoshino, T, 2015) |
| "Testicular cancer is the most frequent malignant disease in young males between 15 and 35 years." | ( Froehner, M; Gudziol, V; Hummel, T; Mitzschke, C; Walliczek-Dworschak, U, 2017) |
| "Testicular cancer is a relatively rare neoplasia, with an incidence of about 1,5% among male malignancies, usually in the third and fourth decade of life." | ( Berretta, M; Capasso, M; Cavaliere, C; D'Aniello, C; Della Pepa, C; Facchini, G; Facchini, S; Imbimbo, C; Iovane, G; Mollo, G; Pesce, L; Pisconti, S; Rossetti, S, 2019) |
| "Testicular cancer is the most commonly diagnosed cancer in men at 15-44 years of age, and radical orchidectomy combined with chemotherapy is currently considered as the standard treatment." | ( Chang, MM; Huang, BM; Pan, BS; Wang, CY, 2019) |
| "Testicular cancer is one of the few tumor types that have not yet benefited from targeted therapy." | ( Cao, K; Chen, H; Gao, X; Jia, Z; Li, J; Lian, B; Liu, Z; Shao, C; Sun, Y; Wang, L; Wang, T; Wang, W; Xu, J; Yang, Q; Zhang, W, 2019) |
| "Testicular cancer is one of the most common malignancy in young men, chemotherapy induced damage in cancerous cells as well as healthy tissue, and we decided to investigate recovery effect of zinc (Zn) on chemotherapy-induced complications in rat chromatin integrity and testicular histomorphometry." | ( Hashemi, F; Khadivi, F; Razavi, S, 2020) |
| "Testicular cancer is the most common cancer type among young men." | ( de Jong, S; de Vries, G; Gietema, JA; Meersma, GJ; Rosas-Plaza, X; Suurmeijer, AJH; van Vugt, MATM, 2020) |
| "Testicular cancer is rare, but its incidence is expected to rise." | ( Ambrosini, V; Calabrò, D; Telo, S, 2020) |
| "Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy." | ( Buchler, T; Kohout, P; Rozsypalova, A; Semerad, O; Tomesova, J; Vejmelka, J, 2022) |
| "Testicular cancer is a public health problem." | ( El-Diasty, HH; El-Ghaweet, HA; El-Sayyad, H; Refaat, S, 2021) |
| "Testicular cancer is relatively uncommon, but at the same time, it is the most common solid tumor in men between the ages of 20 and 34 years." | ( Capogrosso, P; Caspani, F; Chini, C; De Palma, D; Dehò, F; Garutti, L; Nigro, O; Ogliari, FR; Proserpio, I; Tamborini, F; Valdatta, L, 2021) |
| "Testicular cancer is believed to originate from disruptions of normal androgen-estrogen balance in-utero." | ( Bräuner, EV; Glazer, CH; Hauser, R; Juul, A; Lim, YH; Uldbjerg, CS, 2022) |
| "Testicular cancer is a curable cancer." | ( Cheng, L; Chovanec, M, 2022) |
| "Testicular cancer is a curable cancer." | ( Cheng, L; Chovanec, M, 2022) |
| Excerpt | Reference |
|---|
| "Fifty patients with disseminated testicular cancer were treated with a three-drug combination consisting of cis-diamminedichloroplatinum, vinblastine, and bleomycin." | ( Donohue, J; Einhorn, LH, 1977) |
| "Fifty patients with disseminated testicular cancer were treated with a three-drug combination consisting of cis-diaminedichloroplatinum, vinblastine, and bleomycin." | ( Donohue, JP; Einhorn, LH, 1977) |
| "Advanced testicular tumors in 34 patients were treated by combination chemotherapy with bleomycin, vinblastine, vincristine, cis platinum and actinomycin D." | ( Beckley, S; Merrin, C; Takita, H, 1978) |
| "Although disseminated testicular cancer is a rare disease, it is highly treatable, and primary physicians, internists and urologists should have some knowledge of its management." | ( Einhorn, LH; Williams, SD, 1979) |
| "In some mice, secretory testicular tumors can be produced by estrogen administration." | ( Russfield, AB, 1975) |
| "Patients with testicular cancer were treated by semicastratio and in some cases by retroperitoneal surgery." | ( Dunzendorfer, U; Weber, W, 1978) |
| "Of 250 testicular tumors treated up to May 1975 233 (93." | ( Vahlensieck, W; Weissbach, L, 1977) |
| "Cytostatic treatment of metastasising testicular cancers has only been of limited value." | ( Höffken, K; Schmidt, CG; Seeber, S; Tingelhoff, J, 1976) |
| "We report about two cases of cancer of the testis occurring 2 and 7 years after Hodgkin's disease treated with combined chemotherapy and radiation therapy." | ( Averous, M; Chevallier, P; Grasset, D; Guiter, J; Iborra, F; Lavabre-Bertrand, T; Rebillard, X; Robert, M, 1992) |
| "Patients with testicular cancer who relapse after primary chemotherapy are still curable and should be treated aggressively with this goal in mind." | ( Saxman, S, 1992) |
| "Eleven patients with testicular cancer, either relapsing after or refractory to cisplatin-based chemotherapy, underwent salvage chemotherapy with high-dose carboplatin (800 mg/m2 on day 1) and high-dose etoposide (500 mg/m2 on days 1, 3 and 5)." | ( Bais, E; Dubbelman, R; Israels, SP; Richel, DJ; Rodenhuis, S; Roodbergen, R; Schornagel, JH; Ten Bokkel Huinink, WW; Vlasveld, LT; Wanders, J, 1992) |
| "Thirty-nine relapse-free testicular cancer patients were interviewed 1-6 years after completion of chemotherapy, in connection with a study of conditioned nausea." | ( Fredrikson, M; Fürst, CJ; Hursti, T; Johansson, S; Peterson, C; Steineck, G, 1992) |
| "Patients with testicular cancer treated with cisplatin can undergo feminization that is understood poorly." | ( Frei, E; Kantoff, PW; LeBlanc, GA; Ng, SF; Waxman, DJ, 1992) |
| "In addition to kidney tumors, testicular cancer was also found in animals cotreated with either estradiol plus keoxifene (2 of 4 hamsters with tumors) or estradiol plus RU 39,411 (3 of 8 hamsters with tumors)." | ( Folse, DS; Liehr, JG; Roy, D, 1992) |
| "Staging of nonseminomatous testicular cancers, as with other tumors, renders important prognostic information and is necessary for making appropriate treatment recommendations." | ( Johnson, DH; Murphy, P, 1991) |
| "Twenty cases of advanced testicular tumors treated primarily by PVB therapy were reviewed." | ( Iwasaki, A; Nakano, E; Seguchi, T; Sonoda, T; Sugao, H, 1990) |
| "Since 1985 44 consecutive patients with testicular cancer have been treated with a modified BEP regimen." | ( Bandhauer, K; Hess, U; Jungi, WF; Morant, R; Schmid, L; Senn, HJ, 1990) |
| "Forty-eight patients with advanced testicular cancer, defined as abdominal mass greater than 10 cm, mediastinal mass greater than 5 cm, more than 20 lung metastases, or visceral organ involvement were treated with an intensive, alternating five-drug regimen consisting of cisplatin 50 mg/m2 d 1-3, etoposide 170 mg/m2 d 1-3, ifosfamide 5 g/m2 d 15, vincristine 2 mg weekly, bleomycin 15 mg/m2 weekly, q d 28." | ( Bergmann, L; Dölken, G; Harstrick, A; Hohnloser, J; Köhne-Wömpner, CH; Lammers, U; Natt, F; Reichhardt, P; Schmoll, HJ; Siegert, W, 1991) |
| "Current chemotherapy for advanced testis cancer has resulted from an orderly sequence of chemotherapy trials that serves as a model for cancer chemotherapy development." | ( Fox, EP; Loehrer, PJ, 1991) |
| "Of 55 patients with testicular cancer, treated by combination chemotherapy including cisplatin, 21 (mean age 35 [21-51] years) were reexamined for late sequelae of the chemotherapy 1-9 years later." | ( Cordes, M; Gräf, KJ; Herrmann, R; Huhn, D; Mathew, M; Nagel, R; Sander, T; Schwabe, HR; Weissbach, L, 1992) |
| "In 53 patients suffering from testicular cancer it was reviewed whether the changes of spermatogenesis due to radiation or chemotherapy are reflected by the sexual hormones (FSH, LH, T)." | ( Barth, V; Hums, R, 1990) |
| "Following chemotherapy for disseminated testicular cancer, 55 patients underwent surgery because of residual tumour." | ( Boetes, C; de Mulder, PH; Debruyne, FM; Mulders, PF; Oosterhof, GO; Theeuwes, AG, 1990) |
| "The treatment of testicular cancer has undergone considerable evolution since the introduction of cisplatin and the widespread recognition of its curative potential in all stages of disease." | ( Muggia, FM, 1985) |
| "Disseminated germ cell testicular cancer proved to be highly sensitive to platinum-containing chemotherapy regimens." | ( de Góes, GM; Simon, SD; Srougi, M, 1985) |
| "Nine patients with testicular cancer were treated with four platinum containing chemotherapy courses." | ( Donker, AJ; Meijer, S; Mulder, NH; Offerman, JJ; Schraffordt Koops, H; Sleijfer, DT; van der Hem, GK, 1985) |
| "Four patients with non-seminomatous testicular tumor who already had brain metastasis were treated with combination chemotherapy." | ( Fujisawa, S; Hayashida, S; Matuyama, H; Sakatoku, J; Shimizu, K; Shinohara, Y; Takihara, H; Tuwa, M; Yamamoto, N; Yanagi, K, 1985) |
| "Advanced testicular cancer is best treated with combination platinum based chemotherapy as primary therapy." | ( Donohue, JP; Rowland, RG, 1985) |
| "Twenty-eight patients with stage-III testicular tumors seen between 1979 and 1984 were analyzed for the effect of delay on diagnosis and chemotherapy and prognosis." | ( Akdas, A; Kirkali, Z; Remzi, D, 1986) |
| "Eighteen patients with testicular cancer refractory to cisplatin, vinblastine and bleomycin (PVB) were treated with a non-cross-resistant regimen including adriamycin, 60 mg/m2 i." | ( Crispino, S; Marchini, S; Monfardini, S; Pizzocaro, G, 1986) |
| "Forty-five patients with disseminated testicular cancer treated with cisplatin, vinblastine and bleomycin +/- adriamycin (PVB +/- A) were studied to establish the impact of chemotherapy on hormonal and reproductive functions." | ( Harsch, U; Hetzel, WD; Kreuser, ED; Schreml, W, 1986) |
| "We examined nine patients with testicular cancer on 2 consecutive days for acute nephrotoxicity while they were undergoing treatment with cis-platinum." | ( Christensen, AB; Groth, S; Nielsen, H; Pedersen, AG; Rørth, M; Sørensen, JB, 1986) |
| "The treatment of testicular cancer has dramatically improved during the past decade." | ( Einhorn, LH, 1987) |
| "Advanced testicular cancer is best treated with cisplatinum-based combination chemotherapy." | ( Kotake, T; Miki, T, 1987) |
| "Although relatively rare, testicular cancer is an important disease because it is the first disseminated solid tumor occurring in adults for which truly effective therapy has been developed." | ( Bergmann, KA, 1987) |
| "Sixteen patients with metastatic testicular cancer were treated with combination chemotherapy including cisplatin (CDDP) at 3- to 4-week intervals for two to five courses." | ( Hida, S; Nishimura, K; Nishio, Y; Okada, K; Okada, Y; Yoshida, O, 1988) |
| "Twenty-one consecutive patients with testicular cancer treated with bleomycin, vinblastine, and cisplatin (PVB) were evaluated for acute vascular ischaemic events during chemotherapy." | ( Glogar, D; Kuzmits, R; Stefenelli, T; Ulrich, W, 1988) |
| "47 patients with advanced germ cell testicular tumors were treated with combination chemotherapy, cis-platinum, vinblastine and bleomycin (PVB)." | ( Ackermann, R; Geiser, M; Hartmann, M; Mumperow, E; Strohmeyer, T, 1988) |
| "Boys with Stage I testicular tumors were treated by orchidectomy alone, whereas, after appropriate surgery, chemotherapy was recommended for children with more advanced testicular tumors or with tumors at other sites." | ( Barnes, JM; Barrett, A; Mann, JR; Pearson, D; Raafat, F; Wallendszus, KR, 1989) |
| "A patient with stage III testicular cancer was treated by 3 courses of BEP therapy and a partial response was obtained." | ( Asano, S; Isaka, S; Ishii, H; Kodo, H; Komori, I; Okano, T; Osa, Y; Shimazaki, J; Yasuda, K, 1989) |
| "Twelve cases of advanced testicular cancer, including 5 cases of seminoma, 3 cases of teratocarcinoma, 1 case of yolk sac tumor, 1 case of embryonal carcinoma and 2 cases of mixed cell type, were treated with cisplatin-vinblastine-bleomycin (PVB) therapy." | ( Ebisui, K; Maegawa, M; Miyakoda, K; Nakagawa, S; Nakao, M; Nukui, M; Sugimoto, K; Takada, H; Toyoda, K; Watanabe, H, 1989) |
| "The strategies developed for treating testicular cancer can probably serve as models for other, more common chemoresponsive tumors." | ( Hesketh, PJ, 1987) |
| "Twenty nonseminomatous testicular cancer patients not pretreated with emetogenic chemotherapy were included in a crossover study of antiemetic therapy." | ( Niederle, N; Schmidt, CG; Schütte, J, 1986) |
| "Patients with testicular tumors receiving the Einhorn combination chemotherapy with cisplatinum administration for five consecutive days were evaluated for signs of glomerular filtration rate impairment by means of serum beta 2-microglobulin measurements before and on days 2 and 5 after cessation of cisplatin administration and then before repeated cycles of the same chemotherapeutic regimen." | ( Petrová-Skalková, D; Svobodová, M; Tauer, Z, 1988) |
| "Patients with testicular cancers (group 1) who received the cumulative CDDP dose of 360-1966 mg (on average 868 mg), the decrease in Ccr and increase in FE beta 2 MG and NAG were temporary during each chemotherapy cycle." | ( Hida, S; Higashi, Y; Kawamura, J; Soeda, A; Yamauchi, T; Yoshida, O, 1985) |
| "VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases." | ( Kinouchi, T; Kiyohara, H; Kotake, T; Kuroda, M; Miki, T; Oda, H; Saiki, S; Usami, M, 1985) |
| "Four patients with testicular tumors were administrated CDDP, bleomycin (BLM) and vinblastine (VBL)." | ( Arakawa, T; Endo, T; Ikeda, S; Ishibashi, A; Kobayashi, K; Koshiba, K; Li, K; Omata, T; Uchida, T, 1984) |
| "Fifteen patients with nonseminomatous testicular cancer underwent multidrug treatment which included cis platinum, Velban and bleomycin." | ( Cartei, G; Daniele, O; Ferrazzi, E; Fiorentino, M; Fornasiero, A; Fosser, V; Paccagnella, A, 1980) |
| "Successful treatment strategies in testicular cancer have yielded a cure rate unparalleled in cancer treatment." | ( Einhorn, LH, 1981) |
| "Two patients with metastatic embryonal testicular cancer achieved complete remission receiving a vinblastine-cyclophosphamide combination chemotherapy." | ( Freund, M; Ostendorf, P; Wilms, K, 1981) |
| "The treatment goal for metastatic testicular cancer is cure." | ( Braun, DW; Cheng, E; Cvitkovic, E; Dukeman, ME; Golbey, RB; O'Hehir, MA; Reynolds, TF; Vugrin, D; Whitmore, WF, 1981) |
| "Advanced malignant testicular tumors can be treated very successfully by chemotherapy." | ( Arnold, H; Fiebig, HH, 1981) |
| "As from 1976 65 patients with advanced testicular cancer (non-seminomatous) were treated with intensive chemotherapy." | ( Delemarre, JF; ten Bokkel Huinink, WW; Van Coevorden, SJ; Van Dongen, JA; Van Hoesel, QG, 1983) |
| "Fifty-seven patients with testicular tumors have been treated with combined chemotherapy (vinblastine, bleomycin and cisplatinum)." | ( Baki, M; Bodrogi, I; Eckhardt, S; Hindy, I, 1983) |
| "Sixty-nine patients with disseminated testicular cancer and no prior retroperitoneal lymphadenectomy treated with cisplatin, vinblastine, and bleomycin with or without doxorubicin were evaluated for semen analysis, serum gonadotropins, and testosterone." | ( Drasga, RE; Einhorn, LH; Patel, DN; Stevens, EE; Williams, SD, 1983) |
| "Sixteen histologically documented testicular cancer specimens obtained at diagnostic procedures following induction chemotherapy with cis-platinum containing regimens were cloned in soft agar." | ( Foster, BJ; Javadpour, N; Ozols, RF, 1983) |
| "Thirteen patients with advanced testicular tumors (seminoma 2, non-seminoma 11) were treated with combination chemotherapy involving BLM, vinca alkaloid and CDDP (BVP) as induction therapy and followed with CPM, VCR and CDDP as maintenance therapy." | ( Fukui, I; Gotoh, S; Higashi, Y; Katoh, M; Kobayashi, N; Sekine, H; Tachibana, Y; Takagi, K; Yamada, T; Yokokawa, M, 1984) |
| "These patients with advanced testicular cancer were treated with chemotherapy until normalization of tumor markers and until there was no further decrease in the size of palpable or radiologically evident masses for 2 successive cycles of chemotherapy." | ( Aston, D; Freiha, FS; Hannigan, JF; Mark, JB; Rouse, RV; Shortliffe, LD; Spaulding, JT; Torti, FM; Williams, RD, 1984) |
| "In patients with testicular cancer every attempt should be made to preserve the patients' fertility during the necessary diagnostic and therapeutic procedures, without a reduction in the high cure rate which is obtained by modern multimodal treatment of testicular cancer." | ( Aakvaag, A; Abyholm, T; Fosså, SD, 1984) |
| "In 10 patients cured for metastatic testicular cancer by combination chemotherapy serum hormone levels and serum agglutinating antibodies were analysed 12 to 35 months after discontinuation of the treatment." | ( Aakvaag, A; Fosså, SD; Klepp, O; Molne, K, 1980) |
| "In combination chemotherapy of testicular cancer ifosfamide has great value as an alternative to bleomycin when the total bleomycin dose has reached a toxic level." | ( Clemm, C; Hartenstein, R; Wilmanns, W, 1982) |
| "The patients with advanced testicular tumors and bladder carcinoma were treated by combination chemotherapies including cis-diamminedichloroplatinum." | ( Ehara, S; Fujii, M; Igawa, M; Ishino, T; Kodama, M; Moriyama, H; Nakatsu, H; Nihira, H; Nishimoto, K; Ukai, R, 1982) |
| "Endocrine therapy is not used in testicular cancer, its value in renal cell carcinoma is limited, whereas it is a dominant form of therapy for prostate cancer." | ( Ekman, P, 1981) |
| "A total of 250 patients with germ cell testicular tumors were treated by PVB chemotherapy between 1982 and 1992." | ( Belan, V; Cársky, S; Hornák, M; Kausitz, J; Matoska, J; Ondrus, D, 1993) |
| "Fifty-nine stage IV disseminated testicular cancer patients underwent 5 or more courses of cisplatin, vinblastine and bleocin (PVB) chemotherapy from August 1981 to July 1989." | ( Koynov, KD; Tzekova, VI; Velikova, MT, 1993) |
| "Four patients with testicular cancer, who had high-risk malignancy, were treated with high-dose etoposide (500 mg/m2 x 4 days) in order to collect peripheral blood stem cells." | ( Abe, T; Fujii, H; Kuzuyama, Y; Mikami, K; Nakagawa, S; Sonoda, Y; Sugimoto, K; Watanabe, H, 1994) |
| "We presented 15 patients with advanced testicular cancer treated with to 7 courses (mean: 3." | ( Kawai, T; Kawakami, S; Ohono, Y; Ueda, T; Yamauchi, T; Yonese, J, 1994) |
| "Patients with testicular cancer can be cured by cisplatin-based chemotherapy in many cases." | ( Budinsky, A; Eibl, MM; Kaider, A; Krainer, M; Kratzik, C; Michl, I; Wiltschke, C; Wolf, H; Zielinski, CC, 1995) |
| "Because treatment of testicular cancer has improved dramatically during the past 15 years, about 70% of the patients can be relieved of this disease today." | ( Akaza, H; Hayashi, H; Koiso, K; Miyanaga, N, 1995) |
| "The treatment of testicular cancer has undergone considerable evolution since the introduction of cisplatin and widespread recognition of its curative potentials at any stages of disease." | ( Figurin, KM; Garin, AM; Patiutko, IuI; Polotskiĭ, BE; Sokolov, AV; Tiuliandin, SA, 1995) |
| "Four cases with non-seminomatous testicular tumor in stage III completed chemotherapy with POMB/ACE." | ( Asano, K; Kawahara, M; Masuda, F; Shirakawa, H, 1995) |
| "Fifty-one patients with testicular cancer were selected for evaluation of their testicular function, including spermatogenesis and endocrinological function, before and after chemotherapy with anti-cancer agents." | ( Akagashi, K; Itoh, N; Kumamoto, Y; Nambu, A; Nitta, T; Tsukamoto, T, 1995) |
| "In EP chemotherapy against testicular tumor, G-CSF was started on the 9th day and continued for 5 days." | ( Kawakami, M; Kobayashi, S; Niwakawa, M; Ogawa, A; Okaneya, T; Tsuruta, T, 1993) |
| "In patients with advanced germ cell testicular cancer preference must be given to early beginning of intensive chemotherapy without tissue diagnosis of primary tumor by orchiectomy." | ( Hornák, M; Matoska, J; Ondrus, D, 1993) |
| "Apart from contralateral testicular cancers, which are not treatment-related, a largely elevated inherited risk for secondary cancers in patients with germ cell tumors seems unlikely." | ( Bokemeyer, C; Schmoll, HJ, 1995) |
| "Treatment for testicular cancer is associated with a small, but clearly identifiable, risk for secondary solid tumors that can be attributed to radiotherapy, and for secondary leukemia mainly associated with the use of chemotherapy." | ( Bokemeyer, C; Schmoll, HJ, 1995) |
| "For patients with far advanced testicular cancer, who only have a chance of long-term cure in the range of 40% to 50% by standard induction chemotherapy, the German Testicular Cancer Study Group has shown that the application of GM-CSF after PEI chemotherapy has allowed the increase of dose intensity of this three-drug regimen by a factor of 1." | ( Bokemeyer, C; Clemm, C; Harstrick, A; Illiger, HJ; Link, H; Metzner, B; Ostermann, H; Rüther, U; Schmoll, HJ; Siegert, W, 1994) |
| "Twenty-seven patients with advanced testicular cancer underwent cisplatin-based combination chemotherapy and followed by salvage surgery." | ( Kotake, T; Miki, T; Saki, S, 1994) |
| "In patients treated with PEB for testicular cancer, we found strong evidence that the impairment of spermatogenesis is dose-dependent." | ( Giwercman, A; Hansen, SW; Petersen, PM; Rørth, M; Skakkebaek, NE, 1994) |
| "There was one death from testis cancer after radiotherapy and none after adjuvant chemotherapy treatments." | ( Baille-Johnson, H; Edmonds, PM; Jackson, AW; Mott, T; Oliver, RT; Ong, JY; Ostrowski, MJ; Pratt, WR; Williams, MV; Wiltshire, CR, 1994) |
| "Only one patient in the testicular cancer group had Barrett's esophagus of the circumferential type, in addition to typical reflux esophagitis and a hiatal hernia four years after chemotherapy." | ( Kleibeuker, JH; Peters, FT; Sleijfer, DT; van Imhoff, GW, 1993) |
| "We treated 6 patients with testicular cancer." | ( Hashimoto, K; Imai, K; Jinbo, S; Kawashima, K; Kurokawa, K; Matsumoto, K; Suzuki, K; Suzuki, T; Takahashi, H; Yamanaka, H, 1995) |
| "The prognosis of patients with testis cancer classified as being in the advanced extent according to the Indiana University staging system is still poor even when treated with cisplatin based chemotherapy." | ( Harabayashi, T; Kashiwagi, A; Koyanagi, T; Nagamori, S; Nonomura, K; Shinohara, N; Tanaka, M, 1996) |
| "To improve a cure rate of high risk testis cancer, the dose escalation of induction chemotherapy should be considered." | ( Harabayashi, T; Kashiwagi, A; Koyanagi, T; Nagamori, S; Nonomura, K; Shinohara, N; Tanaka, M, 1996) |
| "Based on the diagnosis of right testicular tumor with multiple lung metastasis and L2 vertebral body metastasis, right high orchiectomy and three courses of chemotherapy (peplomycin, etoposide, CDDP) were performed." | ( Hyouchi, N; Kamata, S; Kano, H; Machida, T; Saito, H; Takeuchi, S; Tanizawa, A; Yamada, T, 1996) |
| "Twenty eight patients with germ cell testicular cancer pulmonary metastases received primary chemotherapy including bleomycin, etoposide, and cisplatin (BEP)." | ( Belan, V; Cársky, S; Hornák, M; Kausitz, J; Matośka, J; Ondrus, D; Schnorrer, M, 1996) |
| "One hundred and nine patients with testicular tumors were treated in our hospital between 1970 and 1994." | ( Furuhata, A; Ogawa, K; Ogawa, T; Ooshiba, M, 1996) |
| "The German Testicular Cancer Study Group uses a paclitaxel (Taxol, ifosfamide, cisplatin; TIP) combination regimen as salvage treatment." | ( Beyer, J; Bokemeyer, C; Hartmann, JT; Jonas, U; Kanz, L; Kuczyk, MA; Truss, MC, 1996) |
| "In a randomized trial, the German Testicular Cancer Study Group compared a combination regimen of carboplatin, etoposide and bleomycin (CEB) to standard cisplatin, etoposide and bleomycin (PEB) chemotherapy for patients with 'minimal-' and moderate-disease' non-seminomatous germ cell tumors, according to the Indiana University classification." | ( Bokemeyer, C; Harstrick, A; Haupt, A; Köhrmann, O; Räth, U; Schmoll, HJ; Schöffski, P; Tischler, J; Weissbach, L, 1996) |
| "The incidence of a contralateral testicular tumor among 365 consecutive patients with a nonseminoma testicular tumor, diagnosed in the period 1980 and 1995, was established and related to previous therapy." | ( Droste, JH; Hoekstra, HJ; Schraffordt Koops, H; Sleijfer, DT; van Basten, JP; van Driel, MF, 1997) |
| "To evaluate whether males with testicular cancer treated with chemotherapy including cisplatin (Qt-C) develop an increase in serum cholesterol and triglyceride levels and in the body mass index (BMI), which might pose a cardiovascular risk." | ( Angulo, A; del Palacio, A; Fernández-Miranda, C; Lianes, P; Paz-Ares, L; Schoebel, N, 1997) |
| "In males with testicular cancer treated with Qt-C, no long term increase in cholesterol, triglyceride, and BMI values was detected, which might predispose to the development of cardiovascular diseases." | ( Angulo, A; del Palacio, A; Fernández-Miranda, C; Lianes, P; Paz-Ares, L; Schoebel, N, 1997) |
| "Patients with advanced testicular cancer (TC) have a very good long-term prognosis owing to cisplatin-based polychemotherapy." | ( Emmerich, B; Hasford, B; Hohnloser, JH; Schierl, R, 1996) |
| "We conclude that even bilateral testicular cancer and/or CIS do not preclude fertility and, therefore, patients should be offered andrological investigation and therapy, including possibly surveillance strategy or the chance for cryopreservation of the semen prior to further treatment in order to preserve their chances for paternity." | ( Behre, HM; Bergmann, M; Hertle, L; Kliesch, S; Nieschlag, E, 1997) |
| "In patients with germ cell testicular tumors, high MT expression, as detected by immunohistochemistry, predicts a better response rate to chemotherapy whereas tumors lacking or demonstrating low MT expression show a worse prognosis." | ( Bak, M; Bodrogi, I; Eid, H; Géczi, L; Institoris, E, 1998) |
| "A rare form of testicular cancer, rete testis carcinoma, was observed in five percent of male mice treated in utero with DES." | ( Li, S; McLachlan, JA; Negishi, M; Newbold, RR, 1998) |
| "18 men with testicular cancer has been treated in Institute of Oncology in Warsaw." | ( Demkow, T; Faundez, R; Madej, G, 1998) |
| "Four patients with advanced testis cancer were treated by high-dose chemotherapy supporting by autologous peripheral blood stem cell transplantation." | ( Akasaka, Y; Igarashi, H; Kondou, N; Kuroda, A; Madarame, J; Nakata, J; Ohishi, Y; Tomita, M; Yanada, S, 1998) |
| "We report a case of relapsed testicular tumor complicated by neutropenic enterocolitis during high dose chemotherapy with PBSCT." | ( Haga, N; Honda, K; Itoh, M; Muraki, O; Ohto, H; Tsuruya, Y; Yamaguchi, O, 1998) |
| "For giant testicular tumor with extensive invasion to the spermatic cord, initial chemotherapy followed by surgical resection appears to be a better management." | ( Fukui, I; Izutani, T; Kin, T; Kitsukawa, S; Maeda, Y; Shishido, T; Yonese, J, 1999) |
| "Four testis cancer patients, who 6 years earlier had been treated with etoposide and other cytostatic drugs, showed TCRbeta/gamma VF similar to that in healthy controls." | ( Fuscoe, JC; Hagmar, L; Hellgren, D; Lambert, B; Meydan, D; Nilsson, T; Törnblom, M, 1999) |
| "The high-curability of testicular cancer, along with young age of afflicted patients, can result in patients living for many years after the initial treatment." | ( Akaza, H; Kawai, K, 1999) |
| "Since 1980, 73 patients with advanced testicular cancer have been treated with chemotherapy and 43 patients received post-chemotherapy (salvage) surgery." | ( Kinouchi, T; Kotake, T; Kuroda, M; Maeda, O; Meguro, N; Miki, T; Saiki, S; Usami, M, 1999) |
| "The prognosis of advanced testicular cancer has improved considerably after the introduction of cisplatin-based combination chemotherapy." | ( Hansen, SW; Petersen, PM, 1999) |
| "However, in testis cancer patients EPO treatment should generally be preferred to blood transfusions since cure rates are excellent and thus the potential risks of transfusion-related infections are significant." | ( Albers, P; Heicappell, R; Schwaibold, H; Wolff, J, 2001) |
| "Two cases of testicular tumors with lymph node involvement and multiple lung and liver metastases were treated successfully with intra-arterial infusion chemotherapy." | ( Moriyama, N; Muranaka, K; Tanase, K; Tawada, M, 2000) |
| "Patients cured of metastatic testicular cancer with cisplatin chemotherapy may suffer late adverse effects even after 20 years." | ( Alt, F; Franke, JP; Gelevert, T; Gietema, JA; Meinardi, MT; Messerschmidt, J; Sleijfer, DT; Uges, DR, 2001) |
| "Adjuvant chemotherapy in low-stage testis cancer is an accepted treatment option for two clinical situations: (1) chemotherapy after complete removal of the primary tumor by orchidectomy without clinical evidence of metastasis (clinical stage I), and (2) chemotherapy after complete surgical removal of non-seminomatous retroperitoneal metastases up to 5 cm in greatest transverse diameter by retroperitoneal lymph node dissection in clinical stage II." | ( Albers, P; Melchior, D; Perabo, FG; Siener, R, 2001) |
| "Recurrence pattern of metastatic testicular cancer after the initial treatment was investigated." | ( Hoshi, S; Orikasa, S; Suzuki, K, 2001) |
| "All patients presenting with metastatic testis cancer should be treated with the goal of cure." | ( Sweeney, C, 2001) |
| "After BEP chemotherapy for testicular cancer with G-CSF, neutrophil function was not at all inferior to those before treatment." | ( Itoh, K; Kubota, Y; Nakada, T; Ohji, H; Sasagawa, I, 2001) |
| "Approximately 50% of these testicular cancer patients will subsequently be cured with salvage chemotherapy with tandem transplant of high-dose chemotherapy with peripheral stem cell rescue." | ( Einhorn, LH, 2002) |
| "In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy." | ( Belan, V; Breza, J; Hornák, M; Kausitz, J; Mat'oska, J; Ondrus, D; Schnorrer, M, 2001) |
| "The treatment strategy for testicular cancer using chemotherapy has been well established and has been shown to be successful." | ( Akaza, H; Hattori, K; Kawai, K; Miyanaga, N; Shimazui, T; Tsukamoto, S; Uchida, K, 2002) |
| "The high curability of testicular cancer, along with the young age of afflicted patients, can result in patients living for many years after the chemotherapy." | ( Kawai, K, 2002) |
| "50 Patients with testicular cancer underwent chemotherapy based on cisplatin." | ( Demkow, T; Faundez, R; Kamoda, J, 2002) |
| "Thromboembolic events in testicular cancer patients during cisplatin-containing chemotherapy, both arterial and venous, pose an important problem for various reasons." | ( Gietema, JA; Nuver, J, 2003) |
| "Bleomycin is to treat patients with testicular cancer and lymphoma." | ( Huls, G; ten Bokkel Huinink, D, 2003) |
| "Ninety chemotherapy-treated testicular cancer patients (median follow-up of seven years) were compared with 44 patients after orchidectomy only and 47 healthy men." | ( Burgerhof, JG; Gietema, JA; Hoekstra, HJ; Nuver, J; Sleijfer, DT; Sluiter, WJ; Smit, AJ; van den Berg, MP; van der Meer, J; van Gessel, AI; van Roon, AM, 2004) |
| "We describe three testicular cancer patients who were cured with chemotherapy but developed bilateral osteonecrosis of the femoral head 17, 22 and 55 months after chemotherapy." | ( de Rooy, J; de Wit, R; DeMulder, P; van den Berkmortel, F, 2004) |
| "Metastasis of testicular neoplasm was suspected and chemotherapy with Bleomycin, Etoposide, and Cisplatin was started." | ( Akamatsu, S; Inoue, K; Nishio, Y; Tsukazaki, H, 2004) |
| "Chemotherapy-treated testicular cancer survivors have a lower E/A-ratio than healthy subjects from the general population, which may indicate impaired relaxation of the left ventricle and reflect the high prevalence of cardiovascular risk factors previously reported in these men." | ( Gietema, JA; Hoekstra, HJ; Nuver, J; Sleijfer, DT; Sluiter, WJ; Smit, AJ; van den Berg, MP; van der Meer, J; van Gessel, AI; van Roon, AM, 2005) |
| "Cisplatin-based chemotherapy for testicular cancer results in temporary azoospermia in most men, with a recovery of spermatogenesis in about 50% of the patients after 2 years and 80% after 5 years." | ( Howell, SJ; Shalet, SM, 2005) |
| "The majority of metastatic testicular cancer patients, in contrast to most other metastatic solid tumours, can be cured with highly effective cisplatin-based chemotherapy." | ( de Jong, S; di Pietro, A; Gietema, JA; Spierings, DC; Vries, EG, 2005) |
| "Most patients with advanced testicular cancer can be cured with cisplatin-based chemotherapy." | ( Akaza, H; Hinotsu, S; Hisamatsu, E; Kawai, K; Miyanaga, N; Shimazui, T, 2005) |
| "In 65 testicular cancer patients (median age, 27 years; range, 18 to 48 years), we measured the following cardiovascular parameters before and within 10 weeks after completion of cisplatin-based chemotherapy: platelet numbers, plasma levels of hemostatic and fibrinolytic factors, 24-hour ambulatory blood pressure, baroreflex sensitivity, intima-media thickness of the common carotid artery, and flow-mediated vasodilation of the brachial artery." | ( Gietema, JA; Hoekstra, HJ; Meinardi, MT; Nuver, J; Sleijfer, DT; Smit, AJ; van den Berg, MP; van der Graaf, WT; van der Meer, J; van Gessel, AI; van Roon, AM, 2005) |
| "Out of 59 nonseminomatous testicular cancer patients with low-volume retroperitoneal disease, serum markers normalized after the first cycle of treatment in 30 cases." | ( Managadze, L; Mezvrishvili, Z, 2005) |
| "A patient with germ cell testicular tumor received polychemotherapy (bleomycin, etoposide, and cisplatin or BEP) for a recurrence of his tumor." | ( Kwan, AS; Palexes, G; Sahu, A, 2006) |
| "Thus, therapy for these testicular tumors infractory to treatment is the most important issue." | ( Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T, 2006) |
| "The control group consisted of 40 testicular cancer patients without chemotherapy (median age 35 years, range 16-54 years)." | ( Biro, K; Bodrogi, I; Gaudi, I; Géczi, L; Nagyiványi, K; Noszek, L; Prekopp, P, 2006) |
| "The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed." | ( Akaza, H; Ando, S; Hinotsu, S; Kawai, K; Miyanaga, N; Oikawa, T; Sekido, N; Shimazui, T, 2006) |
| "Adjustment patterns differ between testicular cancer patients and their partners with patients reporting lowered QoL after completion of chemotherapy." | ( Fleer, J; Gritz, ER; Hoekstra, HJ; Hoekstra-Weebers, JE; Sleijfer, DT; Tuinman, MA; Vidrine, DJ, 2007) |
| "With testicular cancer, a disease with a cure rate of 95%, the challenge is to restore quality of life to pretreatment levels and sustain it long-term." | ( Efstathiou, E; Logothetis, CJ, 2006) |
| "The control group consisted of 40 testicular cancer patients who did not receive chemotherapy, with a median age of 35 years (range 16-54 years)." | ( Biró, K; Bodrogi, I; Gaudi, I; Géczi, L; Nagyiványi, K; Noszek, L; Prekopp, P, 2006) |
| "We identified 173 cisplatin-treated testicular cancer survivors (TCSs) who had participated in a long-term survey that included audiometric testing and lymphocyte sampling." | ( Cvancarova, M; Fossa, SD; Kraggerud, SM; Lothe, RA; Oldenburg, J, 2007) |
| "Human testicular cancer is very sensitive to chemotherapy and radiation therapy and is regarded as a curable cancer." | ( Abarzua, F; Huh, NH; Kumon, H; Nasu, Y; Sakaguchi, M; Takaishi, M; Tanimoto, R, 2007) |
| "Tandem autotransplants for testicular cancer are associated with less treatment-related mortality than a planned single transplant, with no differences in disease-related outcomes or overall survival at 3 years." | ( Akard, L; Bolwell, BJ; Carreras, J; Childs, RW; Gale, RP; Klein, JP; Lazarus, HM; Lill, MC; Logan, BR; Pérez, WS; Rizzo, JD; Stadtmauer, EA; Stiff, PJ, 2007) |
| "Metastatic testicular tumors that have not been successfully treated by means of initial chemotherapy are potentially curable with salvage chemotherapy." | ( Abonour, R; Brames, MJ; Chamness, A; Einhorn, LH; Perkins, SM; Williams, SD, 2007) |
| "Current treatment of testicular cancer is associated with secondary malignancy, infertility, and cytotoxicity." | ( Ivanov, V; Kalinovsky, T; Niedzwiecki, A; Rath, M; Roomi, MW, 2007) |
| "Long-term survivors of testicular cancer (TC) who received cisplatin-based chemotherapy have an increased risk of cardiovascular disease." | ( Carver, JR; Jacobs, LA; Mohler, ER; Palmer, SC; Vaughn, DJ, 2008) |
| "Although the incidences of testicular cancer and Hodgkin's lymphoma have increased in young men over the past decade, combination chemotherapy has improved survival." | ( Chan, P; Hales, BF; O'Flaherty, C; Robaire, B; Vaisheva, F, 2008) |
| "Large databases on testicular cancer survivors were analyzed to further define potentially delayed toxicities of initial treatments for testicular germ cell tumors." | ( Hussain, A; Tummala, MK, 2008) |
| "All 203 patients with testicular cancer who required chemotherapy in the period 1995-2003 were included." | ( Arts, EG; de Bruin, D; de Jong, IJ; Dullaart, RP; Gietema, JA; Hoekstra, HJ; Nuver, J; Sleijfer, DT; Sluiter, WJ, 2009) |
| "We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of >or=5% for developing a fatal cardiovascular event qualify for high-risk status." | ( Aass, N; Bremnes, RM; Dahl, O; Fosså, SD; Haugnes, HS; Klepp, O; Wilsgaard, T; Wist, EA, 2008) |
| "Advances in treatment for testicular cancer that include the coadministration of bleomycin, etoposide, and cisplatin (BEP) have brought the cure rate to higher than 90%%." | ( Chan, D; Delbès, G; Hales, BF; Pakarinen, P; Robaire, B; Trasler, JM, 2009) |
| "The patient with bilateral testicular tumor had retroperitoneal and lung metastases at 23 months after adjuvant chemotherapy, and achieved complete remission again after salvage chemotherapy." | ( Chen, ZF; Han, H; Li, YH; Liu, ZW; Qin, ZK; Ye, YL; Yu, SL; Zhou, FJ, 2008) |
| "Most patients with testis cancer are cured with treatment." | ( Bestwick, J; Murugaesu, N; Oliver, RT; Powles, T; Shamash, J, 2009) |
| "The majority of patients with testis cancer are cured with either a unilateral orchidectomy alone or orchidectomy and chemotherapy." | ( Bestwick, J; Murugaesu, N; Oliver, RT; Powles, T; Shamash, J, 2009) |
| "Eleven patients with unilateral testicular cancer (5 pure seminoma, 6 nonseminoma) and biopsy-proven contralateral TIN underwent chemotherapy." | ( Dieckmann, KP; Georgiew, A; Kleinschmidt, K; Loy, V; Weissbach, L, 2009) |
| "A total of 83 patients treated for testicular cancer were investigated." | ( Koller, A; Kratzik, C; Lackner, JE; Marberger, M; Schatzl, G, 2009) |
| "The control group consisted of 40 testicular cancer patients without chemotherapy." | ( Biró, K, 2009) |
| "Although testicular cancers are highly curable malignancies, conventional cisplatin based therapy often causes important toxicities, not often easily manageable." | ( Bauer, C; Bousquet, G; Le Maignan, C; Lejri, N; Lokiec, F; Misset, JL; Pouliquen, AL, 2011) |
| "Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy were more often troubled by dose-dependent neurological side effects and Raynaud-like phenomena compared with those who were not treated with chemotherapy." | ( Bremnes, RM; Brydøy, M; Dahl, O; Fosså, SD; Hauge, ER; Klepp, O; Oldenburg, J; Wentzel-Larsen, T; Wist, EA, 2009) |
| "Physicians who treat advanced testicular tumors should be aware of the potential complication of acute pulmonary hemorrhage, called choriocarcinoma syndrome, in cases with a high hCG level, which indicates a rapidly progressive and high-volume choriocarcinoma." | ( Akaza, H; Fukuhara, Y; Joraku, A; Kandori, S; Kawai, K; Miyanaga, N; Shimazui, T, 2010) |
| "Overall, the prognosis for testicular cancers is good, which makes the choice of accurate treatment intensity between under- and overtreatment often difficult." | ( Becherer, A, 2011) |
| "The modern treatment of testicular cancer has led to notable improvement in the prognosis of these patients." | ( Mladosievicová, B; Valentová, M, 2011) |
| "If a testicular cancer patient has a mass in the retroperitoneum, a metastasis is often the first suspicion, probably leading to improper diagnosis and overtreatment." | ( Dong, P; Li, XX; Li, YH; Wu, S; Yao, K; Zhang, SQ; Zhang, ZL; Zhou, FJ, 2013) |
| "Sixty-one patients with germ cell testicular cancer or extragonadal germ cell cancer received follow-up from diagnosis of IGCNU to development of STC, initiation of IGCNU-definitive treatment (orchiectomy/radiotherapy), emigration, death, or end of follow-up." | ( Axcrona, U; Brabrand, S; Cvancarova, M; Fosså, SD; Lehne, G, 2012) |
| "Patients with testicular tumors who received cisplatin based chemotherapy showed a significant decrease in the estimated glomerular filtration rate and a significant increase in new onset stage 3 chronic kidney disease compared to patients who received no cycle." | ( Afandiyev, F; Baltacı, S; Bedük, Y; Gülpınar, Ö; Mermerkaya, M; Suer, E; Türkölmez, K, 2013) |
| "We studied 19 testicular cancer patients (age 20-54 years) before, at three and nine months after the start of chemotherapy." | ( Burggraaf, J; de Kam, ML; de Roos, A; Lamb, HJ; Osanto, S; van der Meer, RW; van Elderen, SG; Willemse, PM, 2014) |
| "Most testicular tumor patients are cured by intensive combined chemotherapy with cisplatin, but chemotherapy can induce chronic kidney disease in testicular cancer survivors." | ( Ichioka, D; Inai, H; Kawai, K; Miyazaki, J; Nishiyama, H, 2013) |
| "However, resistance of testicular cancer to cisplatin-based therapy does occur and can be mediated through aberrant levels of the above mentioned key players." | ( de Jong, S; Gietema, JA; Koster, R; Timmer-Bosscha, H; van Vugt, MA, 2013) |
| "We experienced a case of testicular cancer that was successfully treated by salvage chemotherapy comprised of methotrexate, actinomycin D and etoposide (MEA)." | ( Hayashi, T; Ishii, T; Itami, Y; Kobayashi, Y; Minami, T; Nagai, Y; Nozawa, M; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshimura, K, 2013) |
| "Treatment of testicular cancer includes the coadministration of bleomycin, etoposide and cis-platinum (BEP); however, along with its therapeutic benefit, BEP exposure results in extensive reproductive chemotoxic effects, including alterations to sperm chromatin integrity." | ( Hales, BF; Maselli, J; Robaire, B, 2014) |
| "Cultured testicular cancer cells I-10 were treated with different concentration of RA (2." | ( Dong, SY; Han, X; Tong, XH; Yu, BB; Zheng, C, 2013) |
| "Seminoma stage I is the most frequent testis cancer and single-dose carboplatin (AUC7) is an effective and widely used adjuvant treatment." | ( Cathomas, R; Ellis, S; Fehr, M; Geldart, TR; Klingbiel, D; Mead, GM; Nagaraj, N; Simmonds, P; von Moos, R; Wheater, M, 2014) |
| "Human testis and testis cancer specimens from orchidectomies were cultured in 'hanging drops' and effects of activin A and follistatin treatment were investigated in seminoma cultures." | ( Joensen, UN; Jørgensen, A; Loveland, KL; Nielsen, JE; Rajpert-De Meyts, E; Toft, BG; Young, J, 2014) |
| "The Indiana University Testis Cancer database was queried to identify IGCCCG good risk patients who received BEP x3 or EP x4 induction chemotherapy before retroperitoneal lymph node dissection." | ( Cary, KC; Einhorn, LH; Foster, RS; Kaimakliotis, HZ; Masterson, TA; Pedrosa, JA, 2015) |
| "A 33-year-old white man with testicular cancer (seminoma) stage IIIa showed a response in mediastinal lymph node metastases after chemotherapy." | ( Liepe, K, 2015) |
| "When treating testicular cancer cells with HDAC inhibitors as well as the death ligand TNF-related apoptosis-inducing ligand (TRAIL), rapid cell death was observed, which depended on TNFRSF10B expression." | ( Beyer, U; Dobbelstein, M; Krönung, SK; Leha, A; Walter, L, 2016) |
| "From the Danish Testicular Cancer database, we identified all patients who received more than one line of treatment for disseminated disease." | ( Agerbaek, M; Bandak, M; Daugaard, G; Gupta, R; Holm, NV; Kier, MG; Lauritsen, J; Mortensen, MS, 2015) |
| "In 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-h urine samples were collected during follow-up (1-13 years after treatment)." | ( Altena, R; Boer, H; Bunskoek, S; de Vries, EG; Geubels, BM; Gietema, JA; Gietema, JQ; Lefrandt, JD; Meijer, C; Nuver, J; Oosting, SF; Proost, JH; Uges, DR; Vonk, JM; Zwart, N, 2015) |
| "Known long-term effects of testicular cancer treatment, such as paraesthesia, hypogonadism, hypercholesterolaemia and hypertension, are associated with long-term circulating Pt exposure." | ( Altena, R; Boer, H; Bunskoek, S; de Vries, EG; Geubels, BM; Gietema, JA; Gietema, JQ; Lefrandt, JD; Meijer, C; Nuver, J; Oosting, SF; Proost, JH; Uges, DR; Vonk, JM; Zwart, N, 2015) |
| "We treated I-10 Leydig testicular cancer cells of mice with gefitineb at 0, 1." | ( Gao, Q; Ji, J; Li, BB; Tong, XH; Wu, XX; Zhang, XY, 2015) |
| "Chemotherapy-treated testicular cancer survivors are at risk for development of the metabolic syndrome, especially in case of decreased androgen levels." | ( Altena, R; Boer, H; Boezen, HM; Dijck-Brouwer, DAJ; Gietema, JA; Kema, IP; Klont, F; Lefrandt, JD; Meijer, C; Nuver, J; Smit, AJ; van Faassen, M; Westerink, NL; Zwart, N, 2016) |
| "In 173 chemotherapy-treated testicular cancer survivors, hormone levels and cardiometabolic status were evaluated cross-sectionally (median 5 years [range 3-20] after chemotherapy) and correlated with SNPs in SRD5A2." | ( Altena, R; Boer, H; Boezen, HM; Dijck-Brouwer, DAJ; Gietema, JA; Kema, IP; Klont, F; Lefrandt, JD; Meijer, C; Nuver, J; Smit, AJ; van Faassen, M; Westerink, NL; Zwart, N, 2016) |
| "In 369 testicular cancer patients treated with bleomycin and cisplatin at the University Medical Center Groningen between 1978 and 2006, H63D and/or C282Y genotypes were determined with an allelic discrimination assay." | ( Gietema, JA; Lubberts, S; Meijer, C; Nuver, J; van der Schoot, GGF; Walenkamp, AME; Wempe, JB; Westerink, NL; Zwart, N, 2016) |
| "Metastatic testicular cancer (TC) can be cured with bleomycin, etoposide and cisplatin (BEP) chemotherapy." | ( Altena, R; Boer, H; Gietema, JA; Kamphuisen, PW; Lefrandt, JD; Lubberts, S; Meijer, C; Mulder, AB; Nuver, J; Oosting, SF; Smit, AJ; van Roon, AM; Zwart, N, 2016) |
| "In metastatic testicular cancer patients treated with bleomycin, etoposide, and cisplatin (BEP) chemotherapy, bleomycin-induced pneumonitis is a well-known and potentially fatal side effect." | ( Altena, R; Bongaerts, AH; de Vries, EG; den Hollander, MW; Gietema, JA; Lubberts, S; Meijer, C; Nuver, J; Oosting, SF; Walenkamp, AM; Westerink, ND; Wolf, RF, 2016) |
| "A total of 292 cisplatin-treated testicular cancer survivors (1980-1994) participated in a national follow-up study (2007-2008)." | ( Bremnes, RM; Brydøy, M; Fosså, SD; Gundersen, POM; Haugnes, HS; Hjelle, LV; Oldenburg, J; Sprauten, M; Tandstad, T; Wilsgaard, T, 2016) |
| "The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach." | ( Albany, C; Cary, KC; Chovanec, M; Einhorn, L; Hanna, N, 2016) |
| "In this study of testicular cancer patients, we evaluated prognostic factors for outcome and calculated survival after standard chemotherapy." | ( Agerbaek, M; Andersen, KK; Bandak, M; Dalton, SO; Daugaard, G; Hansen, MK; Holm, NV; Johansen, C; Kier, MG; Lauritsen, J; Mortensen, MS, 2017) |
| "Patients with testicular cancer with a high tumor volume have a significant risk of developing a VTT with cisplatin-based chemotherapy." | ( Heidegger, I; Heidenreich, A; Pfister, D; Porres, D; Veek, N, 2017) |
| "This study shows that the majority of testicular cancer survivors had stable testosterone levels after treatment for testicular cancer." | ( Bandak, M; Daugaard, G; Juul, A; Jørgensen, N; Kier, MGG; Lauritsen, J; Mortensen, MS, 2018) |
| "The Indiana University Testis Cancer database was queried to identify IGCCCG good-risk PC-RPLND patients who received either EP × 4 or BEP × 3 induction chemotherapy." | ( Albany, C; Cary, C; Einhorn, LH; Foster, RS; Hanna, NH; Jacob, JM; Masterson, TA, 2018) |
| "Overall, 50 testicular cancer survivors treated from 1990 to 2013 were enrolled." | ( Iwamoto, T; Joraku, A; Kawahara, T; Kawai, K; Kojima, T; Kurobe, M; Miyazaki, J; Nishiyama, H; Suetomi, T; Waku, N, 2018) |
| "In relapsed testicular cancer, post platinum based chemotherapy controversy exists as to the optimum relapse regimen as significant cure rates can be expected by re-treating with both conventional dose and high dose or dose intense regimens." | ( Alifrangis, C; Duncan, S; Ng, K; Shamash, J, 2018) |
| "Chemotherapy for testicular cancer (TC) has been associated with neurotoxic effects shortly post-treatment." | ( Boogerd, W; de Ruiter, MB; Kerst, JM; Kirschbaum, C; Reneman, L; Schagen, SB; Stouten-Kemperman, MM, 2018) |
| "Treatment of malignant testicular cancer is primarily combined surgery with various chemical drugs." | ( Chang, MM; Chen, YC; Cheng, KS; Huang, BM; Kang, FC; So, EC; Wang, SC; Wong, KL, 2019) |
| "Unclassified sex cord-stromal testicular tumor is a rare disease and its treatment has not been established." | ( Mikami, K; Okuno, Y; Takeuchi, T; Toriyama, F; Uekusa, T, 2019) |
| "We studied testicular cancer patients' objective and subjective cognitive function longitudinally, comparing a surgery group with a surgery + chemotherapy group, addressing prior methodological issues using a computerized test to limit assessment issues, and controlling for confounding variables." | ( Davis, ID; Grimison, P; Kalinowski, P; Martin, A; Maruff, P; Olver, IN; Schembri, A; Stockler, M; Toner, GC; Whitford, HS, 2020) |
| "Patients undergoing chemotherapy for testicular cancer differ from findings in breast cancer populations." | ( Davis, ID; Grimison, P; Kalinowski, P; Martin, A; Maruff, P; Olver, IN; Schembri, A; Stockler, M; Toner, GC; Whitford, HS, 2020) |
| "Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause-specific excess mortality has been rarely studied among patients treated in the platinum era." | ( Aarts, MJB; de Jong, IJ; de Wit, R; Gietema, JA; Groenewegen, G; Groot, HJ; Horenblas, S; Hulshof, MCCM; Jóźwiak, K; Lubberts, S; Meijer, OWM; Poortmans, PM; Schaapveld, M; Smilde, TJ; van den Belt-Dusebout, AW; van den Berg, HA; van Leeuwen, FE; Vanneste, BGL; Witjes, JA, 2020) |
| "The randomized "Testicular cancer and Aerobic and Strength Training trial" (TAST-trial) aimed to evaluate the effect of high-intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin-based chemotherapy (CBCT) for testicular cancer (TC)." | ( Brydøy, M; Edvardsen, E; Fosså, SD; Gjerset, GM; Haugnes, HS; Henriksson, CE; Larsen, KO; Negaard, HFS; Raastad, T; Sandset, PM; Tandstad, T; Thorsen, L; Wisløff, T, 2020) |
| "The treatment of testicular cancer includes unilateral orchiectomy and chemotherapy and is curative for most patients." | ( Borbélyová, V; Celec, P; Chovanec, M; Mego, M; Renczés, E, 2020) |
| "PET/CT role in testicular cancer management is mainly for the assessment of seminoma residual masses after therapy (>3 cm)." | ( Ambrosini, V; Calabrò, D; Telo, S, 2020) |
| "To evaluate neurotoxicity in testicular cancer survivors (TCSs) years after treatment and secondly the influence of neurotoxicity on quality-of-life (QoL)." | ( Agerbæk, M; Bandak, M; Daugaard, G; Dysager, L; Kreiberg, M; Lauritsen, J; Rosenvilde, JJ; Skøtt, JW; Wagner, T, 2021) |
| "Treatment with chemotherapy for testicular cancer induces long-term neuro- and ototoxicity which may have severe influence on quality-of-life years after treatment cessation." | ( Agerbæk, M; Bandak, M; Daugaard, G; Dysager, L; Kreiberg, M; Lauritsen, J; Rosenvilde, JJ; Skøtt, JW; Wagner, T, 2021) |
| "Metastatic germ cell cancer of the testis is characterized by favorable prognosis since effective treatment methods are available even in cases of extensive disease." | ( Aziri, R; Chovanec, M; Hulova, S; Kolnikova, G; Mardiak, J; Mego, M; Palacka, P; Pindak, D; Rejlekova, K; Vulev, I, 2020) |
| "We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy." | ( Buchler, T; Kohout, P; Rozsypalova, A; Semerad, O; Tomesova, J; Vejmelka, J, 2022) |
| "To identify all incident cases of testicular cancer treated with bleomycin-based chemotherapy in the Canadian province of Ontario during 2005-2010, the Ontario Cancer Registry was linked with chemotherapy treatment records." | ( Bedard, PL; Booth, CM; Karim, S; Lougheed, MD; Raphael, MJ; Robinson, AG; Wei, X, 2020) |
| "We report a patient in whom a testicular tumor with uncommon metastases occurred 20 years after primary retroperitoneal EGCT treatment." | ( Ando, N; Aoki, S; Hara, K; Hidano, A; Matsubara, K; Morinaga, S; Muramatsu, H; Nakagawa, M; Nishibata, C; Nishikawa, G; Ono, K; Takahashi, I; Tobiume, M; Yamada, Y, 2021) |
| "Using complete information regarding testicular cancer (TC) treatment burden, this study aimed to investigate cause-specific non-TC mortality with impact on previous treatment with platinum-based chemotherapy (PBCT) or radiotherapy (RT)." | ( Bremnes, RM; Fosså, SD; Haugnes, HS; Hellesnes, R; Karlsdottir, Á; Kvammen, Ø; Myklebust, TÅ; Negaard, HFS; Tandstad, T; Wilsgaard, T, 2021) |
| "Adult cisplatin-treated testicular cancer survivors were enrolled." | ( Bedard, PL; Chen, EX; Hamilton, RJ; Hansen, AR; Jarvi, K; Lau, S; Lewin, J; Li, X; Malone, ER; Zhang, WJ, 2022) |
| "Survivors of testicular cancer may experience long-term morbidity following treatment." | ( Conduit, C; Goad, J; Hofman, MS; Koh, TT; Lawrentschuk, N; Lewin, JH; Tai, KH; Toner, GC; Tran, B, 2022) |